Alchemab Therapeutics

Summary active Updated Jul 9, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location London, United Kingdom
Founded 2019
Latest Stage Series A extension
Total Raised £25M Series A extension announced July 2026 (prior £60M Series A)
Website https://www.alchemab.com
Sector
biotech life-sciences drug-discovery antibody-therapeutics healthcare

Founders

Jane Osbourn CEO

About

Alchemab Therapeutics is a London-based biotechnology company founded in 2019 that develops therapeutic antibodies discovered by analysing the immune systems of patients whose bodies naturally resist otherwise progressive diseases 124. On 2026-07-08 the British Business Bank announced a £25 million investment into Alchemab as an extension to the company’s earlier Series A, describing it as its largest direct investment in a life sciences company to date 1234. Alchemab’s prior £60 million Series A (announced 2021) was led by SV Health Investors alongside British Patient Capital, and the company has developed a platform for identifying novel drug targets and therapeutics through analysis of patient antibodies 45. CEO Jane Osbourn told Scrip the British Business Bank commitment is validation of the drug discovery platform’s long-term potential and will allow Alchemab “to grow and thrive in its home country.” 23

Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.

Funding History

Date Round Amount Lead Co-investors
2026-07-08 Series A extension £25M British Business Bank — 1234
2021 Series A £60M SV Health Investors British Patient Capital 5

What Investors Say

No independently sourced investor quotes found for the 2026 round.

What Founders Say

CEO Jane Osbourn, quoted by Scrip: “the £25m investment from the British Business Bank is further validation of the sustainable, long-term potential of the firm’s drug discovery platform which will allow Alchemab to grow and thrive in its home country.” 23

Sources

  1. EU-Startups, “London’s Alchemab Therapeutics secures €29.3 million as British Business Bank makes its largest life sciences investment yet,” July 2026. Accessed July 9, 2026. https://www.eu-startups.com/2026/07/londons-alchemab-therapeutics-secures-e29-3-million-as-british-business-bank-makes-its-largest-life-sciences-investment-yet/↩↩↩

  2. HealthInvestor UK, “Alchemab Therapeutics extends Series A financing,” July 2026. Accessed July 9, 2026. https://healthinvestor.co.uk/alchemab-therapeutics-extends-series-a-financing/↩↩↩↩↩

  3. Scrip / Citeline Insights, “Alchemab Flies Flag For UK Biotechs With Government Backing,” July 8, 2026. Accessed July 9, 2026. https://insights.citeline.com/scrip/business/financing/alchemab-flies-flag-for-uk-biotechs-with-government-backing-BR7MSUYC25A7NMBG3ZB6BSGMZQ/↩↩↩↩

  4. British Business Bank, “Alchemab Therapeutics” case study. Accessed July 9, 2026. https://www.british-business-bank.co.uk/case-studies/alchemab-therapeutics↩↩↩↩

  5. Alchemab Therapeutics press release, “Alchemab raises £60 million ($82 million) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics.” Accessed July 9, 2026. https://www.alchemab.com/alchemab-raises-60-million-82-million-in-series-a-financing-to-advance-novel-platform-for-identifying-disease-modifying-antibody-therapeutics/↩↩